Abstract:Poorly water-soluble weakly basic compounds which are solubilized in gastric fluid are likely to precipitate after the solution empties from the stomach into the small intestine, leading to a low oral bioavailability. In this study, we reported an approach of combining solubilization agents and precipitation inhibitors to produce a supersaturated drug concentration and to prolong such a drug concentration for an extended period of time for an optimal absorption, thereby improving oral bioavailability of poorly water-soluble drugs. A weakly basic compound from Johnson and Johnson Pharmaceutical Research and Development was used as a model compound. A parallel microscreening precipitation method using 96-well plates and a TECAN robot was used to assess the precipitation of the tested compound in the simulated gastric fluid (SGF) and the simulated intestinal fluid (SIF), respectively, for lead solubilizing agents and precipitation inhibitors. The precipitation screening results showed vitamin E TPGS was an effective solubilizing agent and Pluronic F127 was a potent precipitation inhibitor for the tested compound. Interestingly, the combination of Pluronic F127 with vitamin E TPGS resulted in a synergistic effect in prolonging compound concentration upon dilution in SIF. In addition, HPMC E5 and Eudragit L100-55 were found to be effective precipitation inhibitors for the tested compounds in SGF. Furthermore, optimization DOE study results suggested a formulation sweet spot comprising HPMC, Eudragit L 100-55, vitamin E TPGS, and Pluronic F127. The lead formulation maintained the tested compound concentration at 300 μg/mL upon dilution in SIF, and more than 70% of the compound remained solubilized compared with the compound alone at <1 μg/mL of its concentration. Dosing of the solid dosage form predissolved in SGF in dogs resulted in 52% of oral bioavailability compared to 26% for the suspension control, a statistically significant increase (p = 0.002). The enhanced oral bioavailability of the tested compound could be attributed to generation and prolongation of a supersaturated drug concentration in vivo by the solubilizing agents and precipitation inhibitors. The study demonstrates that the combination approach of solubilization agents and precipitation inhibitors provides improved oral bioavailability for a poorly water-soluble weakly basic compound.

Co-Administration of a Water-Soluble Polymer Increases the Usefulness of Cyclodextrins in Solid Oral Dosage Forms

Pharmacokinetics and Enhanced Oral Bioavailability in Beagle Dogs of Cyclosporine A Encapsulated in Glyceryl Monooleate/Poloxamer 407 Cubic Nanoparticles

Characterization and Pharmacokinetics of Dimethyl-β-cyclodextrin Inclusion Complexes of Water Insoluble Drug BMCP25 in Rats

Mechanisms of dissolution and crystallization of amorphous glibenclamide

Enhanced bioavailability of a poorly water-soluble weakly basic compound using a combination approach of solubilization agents and precipitation inhibitors: a case study

Simultaneous solubilization and extended release of insoluble drug as payload in highly soluble particles of γ-cyclodextrin metal-organic frameworks

Cogrinding enhances the oral bioavailability of EMD 57033, a poorly water soluble drug, in dogs

Comprehensive molecular docking and molecular dynamics simulation study of unmodified and modified cyclodextrins: erlotinib inclusion complexes

β‐Cyclodextrin Derivatives, SBE4‐β‐CD and HP–β‐CD, Increase the Oral Bioavailability of Cinnarizine in Beagle Dogs

Effects of 2-hydroxypropyl-beta-cyclodextrin on pharmacokinetics of digoxin in rabbits and humans

Polymersomes Via Self-Assembly of Amphiphilic Β-Cyclodextrin-centered Triarm Star Polymers for Enhanced Oral Bioavailability of Water-Soluble Chemotherapeutics.

Nano-strategies for advancing oral drug delivery: Porous silicon particles and cyclodextrin encapsulation for enhanced dissolution of poorly soluble drugs

Effect of cyclodextrin concentration on the oral bioavailability of danazol and cinnarizine in rats

Effect of Cyclodextrin Complex Formation on Solubility Changes of Each Drug Due to Intermolecular Interactions between Acidic NSAIDs and Basic H2 Blockers

β-Cyclodextrin/dialdehyde glucan-coated keratin nanoparticles for oral delivery of insulin

Cyclodextrin polymer improves atherosclerosis therapy and reduces ototoxicity

Preformulation Studies and Bioavailability Enhancement of Curcumin with a 'Two in One' PEG-β-Cyclodextrin Polymer

Hot liquid extrusion assisted drug-cyclodextrin complexation: a novel continuous manufacturing method for solubility and bioavailability enhancement of drugs

Pharmacokinetics and pharmacodynamics of cyclodextrin-based oral drug delivery formulations for disease therapy

Phase Solubility Behavior of Hydrophilic Polymer/cyclodextrin/lansoprazole Ternary System Studied at High Polymer Concentration and by Response Surface Methodology.

Exploring cyclodextrin-glabridin inclusion complexes: Insights into enhanced pharmaceutical formulations